| 摘要 |
<p>Ligands with a binding affinity for the CD3 antigen having at least one CDR which is of different origin to the variable framework region and/or the constant region of the ligand, the at least one CDR being selected from the amino acid sequences: (a) Ser-Phe-Pro-Met-Ala, (b) Thr-Ile-Ser-Thr-Ser-Gly-Gly-Arg-Thr-Tyr-Tyr-Arg-Asp-Ser-Val-Lys-Gly, (c) Phe-Arg-Gln-Tyr-Ser-Gly-Gly-Phe-Asp-Tyr, (d) Thr-Leu-Ser-Ser-Gly-Asn-Ile-Glu-Asn-Asn-Tyr-Val-His, (e) Asp-Asp-Asp-Lys-Arg-Pro-Asp, (f) His-Ser-Tyr-Val-Ser-Ser-Phe-Asn-Val, and conservatively modified variants thereof, are of therapeutic value, particularly in the control of graft rejection.</p> |
